Related by context. All words. (Click for frequent words.) 58 IPL# 54 4SC 52 almorexant 51 PF # [001] 51 AEGR 51 phase IIa 51 safinamide 51 AEZS 50 Lu AA# 50 Jingxin Pharma 50 JAK inhibitor 50 CRx 50 ALKS 49 GLPG# 49 Lacosamide 49 Phase IIa clinical 49 NKTR 49 highly selective inhibitor 49 ELND# AZD 48 ibudilast 48 volociximab 48 CCR5 antagonist 48 phase IIa clinical 48 R#/MEM # 48 Phase IIa 48 Tasimelteon 48 ELND# 48 MT# MEDI 48 cathepsin K inhibitor 48 ocrelizumab 48 Anticalin R 48 ADX# 48 Anavex #-# 48 NP2 Enkephalin 48 ITMN 48 ARRY 47 CEROVIVE NXY 47 Phase IIa trials 47 R#/MEM 47 XL# [003] 47 CXA 47 subtype selective NMDA receptor 47 PDE4 inhibitor 47 DermaVir Patch 47 desvenlafaxine 47 tasimelteon 47 MEK inhibitor 47 Vilazodone 47 Zoraxel 47 HGS# 47 polymerase inhibitor 47 Pimavanserin 47 cannabinor 47 HMPL 47 adipiplon 47 AstraZeneca Targacept 47 RhuDex ® 47 bicifadine 47 SRT# [003] 47 Safinamide 47 MAP# 47 ALTU 47 cariprazine 47 BMN 47 lurasidone 46 pharmacokinetics PK 46 Rotigotine 46 EndoTAG TM -1 46 ramelteon 46 Corlux 46 Multiple Ascending Dose 46 rNAPc2 46 vilazodone 46 Valdoxan 46 phase IIb 46 PRT# 46 Bremelanotide 46 LEVADEX 46 KRN# 46 ancrod 46 pan HDAC inhibitor 46 ATL# [002] 46 Debio 46 DU #b 46 OXi# 46 TriRima 46 SUVN 46 Gaboxadol 46 Desmoteplase 46 AZILECT R 46 opioid induced bowel dysfunction 46 phase Ib 46 VEGF Trap 46 single ascending dose 46 RVX 46 Almorexant 46 opioid analgesic 46 PRX# 46 BNC# 45 fostamatinib 45 PRX # 45 fluvoxamine 45 receptor agonist 45 generation FBPase inhibitor 45 sargramostim 45 TheraQuest 45 tezampanel 45 Phase Ib clinical 45 Phase 2a trial 45 nucleoside polymerase inhibitor 45 CUDC 45 RG# [001] 45 favorable pharmacokinetic profile 45 JVRS 45 long acting muscarinic 45 ponatinib 45 Archexin 45 CERE 45 LEVADEX ™ 45 gaboxadol 45 dacetuzumab 45 SAR# [002] 45 phase IIb trial 45 TMC# [002] 45 elotuzumab 45 EGb 45 pramipexole 45 schizophrenia CIAS 45 Sublinox 45 subcutaneously administered 45 Adenoscan 45 eszopiclone 45 Synavive 45 Cimzia ® certolizumab pegol 45 Intermezzo R 45 Pharmacokinetic studies 45 brivaracetam 45 orally bioavailable 45 GLYX 45 Santhera 45 Prodarsan ® 45 XOMA 45 generation purine nucleoside 45 nicotinic alpha 7 45 receptor antagonist 45 Functional Dyspepsia 45 serotonin norepinephrine reuptake inhibitor 45 PN# [003] 45 NVA# 45 rufinamide 45 placebo controlled clinical 45 liposomal formulation 45 Phase III clinical 45 humanized anti 45 levodopa induced dyskinesia 45 davunetide intranasal AL 45 mertansine 45 Zenvia Phase III 45 DG# [001] 45 Phase IIa trial 45 Aflibercept 45 IV APAP 45 oral prodrug 45 ARQ 45 MEDI 45 HZT 45 sorafenib Nexavar 45 AZD 44 receptor tyrosine kinase inhibitor 44 mGluR2 NAM 44 ACUROX ® 44 Phase Ib study 44 dyskinesia PD LID 44 Lodotra 44 ELND-#/AZD-# 44 Capesaris 44 sublingual formulation 44 AZD# 44 TG# [003] 44 mGluR2 positive 44 ralfinamide 44 Amplimexon 44 pimavanserin 44 PKC# 44 trospium 44 Mirapexin 44 Omnitarg 44 CG# [003] 44 tanespimycin 44 atypical antipsychotic 44 Gabapentin GR 44 Phase 2a 44 ICA # 44 histone deacetylase HDAC inhibitor 44 positive allosteric modulator 44 Apoptone 44 SAR# [004] 44 veltuzumab 44 Phase Ib 44 dopamine agonist 44 Anticalin ® 44 Sycrest 44 XL# XL# XL# 44 GSK# [002] 44 orally inhaled migraine 44 Fc fusion protein 44 multiple ascending dose 44 orally administered 44 NeuroSearch 44 amyloid imaging 44 Parkinson disease levodopa induced 44 Solulin 44 enzastaurin 44 GSK# [001] 44 atacicept 44 lacosamide 44 Tanespimycin KOS 44 PRIALT 44 INGN 44 CD# antibody [001] 44 Circadin 44 GV# [001] 44 PN# [001] 44 non nucleoside inhibitor 44 BCR ABL inhibitors 44 ProSavin 44 MoxDuo TM IR 44 DDP# 44 mometasone furoate 44 alemtuzumab Campath 44 ADAGIO study 44 ANAVEX #-# [003] 44 Phase IIb clinical 44 Traficet EN 44 NGX# 44 MoxDuo 44 INT# [002] 44 IMGN# 44 casopitant 44 ADL# 44 vidofludimus 44 Vernakalant 44 investigational protease inhibitor 44 Ocrelizumab 44 Insegia 44 CIMZIA TM 44 Tyrima 44 acting muscarinic antagonist 44 Pertuzumab 44 Acute Ischemic Stroke 44 Actilon 44 Phase 2a clinical 44 trabedersen 44 Staccato loxapine 44 multicenter Phase III 44 Fibrin Pad 44 indacaterol 44 Indiplon 44 prospective randomized multicenter 44 Phase 1b clinical 44 TBC# 44 XL# XL# 44 Multicenter 44 Bosutinib 44 CRF1 receptor antagonist 44 pharmacokinetic profile 44 Phase IIB 44 PDE# inhibitors 44 PHX# 44 ALGRX 44 huN# DM1 44 Phase 2b clinical 44 Phase IIb 44 Phase 2b 44 becocalcidiol 44 efficacy tolerability 44 zonisamide SR 44 Phase 2b study 44 Antiviral Activity 43 Kahalalide F 43 Serdaxin 43 resolvin 43 Neupro R 43 ACTEMRA TM 43 TRO# 43 CF# [002] 43 transient insomnia 43 triptan 43 Staccato zaleplon 43 XOPENEX HFA 43 bardoxolone 43 NOX E# 43 Versartis 43 alpha 2b 43 Phase IIa clinical trials 43 obatoclax 43 Sapacitabine 43 PD LID 43 BGC# 43 TASQ 43 MORAb 43 antagonist LAMA 43 huC# DM4 43 purine analog 43 Ostarine 43 Anticalin 43 Hsp# inhibitor 43 nitric oxide donating 43 Iloperidone 43 Gencaro 43 asenapine 43 intranasal formulation 43 doxepin 43 donepezil Aricept 43 phase IIb study 43 Pharmacokinetic analyzes 43 Onrigin 43 RhuDex 43 antisense oligonucleotide 43 APD# 43 Telaprevir VX 43 acetylcholinesterase inhibitor 43 Neupro 43 Apitope 43 2A receptor agonist 43 Aurora Kinase 43 Medoxomil 43 Vicriviroc 43 bucindolol 43 zaleplon 43 Epratuzumab 43 Menarini 43 Zelrix 43 CorVue ™ 43 EOquin 43 pramlintide 43 rxRNA 43 selective adenosine 43 CBLC# 43 double blinded randomized 43 RezularTM 43 Ozarelix 43 SNT-MC#/idebenone 43 CCR9 antagonist 43 IV Busulfex 43 Fx #A 43 Phase #/#a 43 Phase 2b clinical trials 43 desvenlafaxine succinate 43 oral antiviral 43 castrate resistant prostate cancer 43 5 HT3 receptor 43 Milnacipran 43 VeriStrat 43 VQD 43 iCo 43 CATIE AD 43 Alexza 43 alagebrium 43 Solzira 43 Zenvia ™ 43 Apaziquone 43 HCV protease inhibitor 43 HCV NS5B polymerase 43 tapentadol ER 43 omacetaxine mepesuccinate 43 WILEX 43 Cleviprex TM clevidipine 43 Catena ® 43 mirtazapine 43 SPC# [001] 43 Cannabinor 43 Donepezil 43 budiodarone 43 MabThera rituximab 43 subcutaneous formulation 43 5 HT2A 43 SARMs 43 peripherally acting 43 SEROQUEL 43 afamelanotide 43 custirsen 43 INKP 43 BIBW 43 bendamustine 43 selective A1 adenosine 43 SNRI 43 regadenoson 43 otelixizumab 43 EOquin TM 43 linaclotide 43 Phenoptin 43 Abilify aripiprazole 43 refractory CLL 43 afatinib 43 ganetespib 43 ATL# [001] 43 SPP# Rasilez 43 antibody MAb 43 PS# [001] 43 oral anticoagulant 43 favorable tolerability 43 LUNESTA 43 renin inhibitors 43 relapsed multiple myeloma 43 teriflunomide 43 pitavastatin 43 GA# [003] 43 RSD# 43 Bicifadine 43 PsychoGenics 43 HuMax CD# 43 lintuzumab 43 Simulect 43 beta 1a 43 HDAC Inhibitor 43 Keryx Biopharma 43 interferon beta 1b 43 Memryte 43 KX2 43 EXPAREL TM 43 Addex 43 nalmefene 43 Naproxcinod 43 oral antiplatelet agent 43 phase IIb clinical 43 MEK inhibitor ARRY 43 partial agonist 43 JP-#/fipamezole 43 telcagepant 43 PI3K/Akt pathway inhibitor 43 pharmacodynamic PD 43 P#X# antagonist 43 preclinical 43 INCB# [001] 43 rasagiline tablets 43 aclidinium bromide 43 PSN# [001] 43 Onbrez Breezhaler 43 Phase Ib II 43 COPAXONE 43 evaluating tivozanib 43 Onconase 43 KNS # 43 Pharmacokinetic 43 Prosaptide 43 inhibitor RG# 43 Meets Primary Endpoint 43 Genentech Roche 43 plus prednisone 43 Pancreate 43 #D#C# 43 Varenicline 43 bapineuzumab AAB 43 carfilzomib 43 Sym# 42 abiraterone acetate 42 Serdaxin ® 42 Bifeprunox 42 Ofatumumab 42 Phase IIa proof 42 IMiDs ® 42 serotonin reuptake inhibitor 42 antithrombotic 42 rilonacept 42 Daclizumab 42 SCY 42 proteasome inhibitor bortezomib 42 Benazepril 42 radiation sensitizer 42 NasalFent 42 ARIKACE ™ 42 ropinirole Requip 42 lixisenatide 42 AZD# ARRY 42 pertuzumab 42 placebo controlled Phase 42 Phase 1b trial 42 Oral NKTR 42 selective antagonist 42 selective GR 42 RSD# oral 42 fosbretabulin 42 resminostat 42 bupropion SR 42 Clonicel 42 Nanocort 42 TLR agonists 42 temsirolimus 42 nucleotide analog 42 PEG INTRON 42 Onalta 42 Relovair 42 M6G 42 Silodosin 42 mapatumumab 42 Adentri 42 IPX# 42 eniluracil 42 beta secretase inhibitor 42 renin inhibitor 42 Phase 2a Trial 42 Phase #b/#a trial 42 novel mTOR inhibitor 42 AGGRASTAT ® 42 PFO closure 42 RH1 42 regorafenib 42 Dabigatran etexilate 42 MoxDuo ® IR 42 VELCADE melphalan 42 Vascular Disrupting Agent 42 vivo preclinical 42 Phase IIb trial 42 KB# [002] 42 proteasome inhibitor 42 canakinumab 42 investigational drug 42 subtype selective 42 Cimzia TM 42 clevidipine 42 JAK Inhibitor 42 Mipomersen 42 Phase 1a clinical 42 Receptor Antagonist 42 HuMax EGFr 42 INVEGA SUSTENNA 42 VMAT2 42 quetiapine 42 XTL 42 SILENOR 42 Symphogen 42 QT QTc 42 MicroThermX Microwave Ablation System 42 Phase 1b 42 ACAPODENE R 42 AVE# 42 levetiracetam 42 interferon beta 1a 42 Phase Ib clinical trials 42 pharmacodynamic profile 42 Rasagiline 42 AV# [003] 42 novel prodrug 42 mTOR inhibitor 42 Levetiracetam 42 Initiate Phase 42 Serdolect ® 42 Q#IR 42 2DG 42 evaluating Vectibix 42 Phase 2a proof 42 HQK 42 tafamidis 42 Othera 42 Luveniq 42 treat opioid induced 42 LY# [002] 42 flupirtine 42 GATTEX 42 Alzhemed TM 42 5 HT6 antagonist 42 ATACAND 42 divalproex sodium 42 Symetron 42 Triolex 42 Trophos 42 OncoVEX GM CSF 42 visilizumab 42 selegiline 42 pharmacokinetic 42 CGEN 42 ruxolitinib 42 Aptivus ® 42 ONTAK 42 Phase #b/#a 42 edoxaban 42 Azixa 42 Intermezzo ® 42 Phase 2a Clinical Trial 42 Sanvar R 42 multicentre randomized double 42 GW# [003] 42 GlycoPEG GCSF 42 DuraSite 42 dose escalation trial 42 Betaferon ® 42 Symadex 42 GAMMAGARD 42 ANG# 42 Small Modular SMIP 42 reslizumab 42 BAY #-# 42 lesinurad 42 TRX1 42 baminercept 42 Dual Opioid 42 VentiRx 42 Procoralan 42 trodusquemine 42 Staccato alprazolam 42 lomitapide 42 Locteron 42 Tarceva TM 42 anticancer agent 42 cortical stimulation 42 Evoltra 42 TLR8 agonist 42 Laquinimod 42 ANCHOR trial 42 ProMune 42 #HT#A 42 TMC# C# 42 erlotinib Tarceva 42 rasagiline 42 Omiganan 42 #F AV 42 tipifarnib 42 Nymox 42 Sunovion Pharmaceuticals Inc. 42 synthetic anthracycline 42 BiTE 42 briakinumab 42 cilengitide 42 SILENOR TM 42 MET inhibitor 42 Aurora kinase inhibitor 42 OvaRex MAb 42 daclizumab 42 Galenea 42 CMX# [001] 42 RG# ITMN 42 Raptiva ® 42 BRAF inhibitor 42 Arcalyst 42 anti amnesic 42 miconazole Lauriad ® 42 ocular hypertension 42 CCR5 inhibitor 42 tecarfarin 42 AEG# 42 MB# [004] 42 Neurim Pharmaceuticals 42 DNage 42 Decitabine 42 Ambrisentan 42 CONCERTA 42 Oral Insulin 42 RAPAFLO 42 Bendavia 42 mesylate 42 Duloxetine 42 sevelamer carbonate 42 midstage clinical 42 pharmacotherapies 42 Lodotra TM 42 topical INCB# 42 Nanobody 42 TREANDA 42 Alexza Staccato 42 Febuxostat 42 SGLT2 inhibitor 42 citalopram 42 dopamine partial agonist 42 TASKi3 42 INC# 42 Parkinson disease PD 42 intravenously administered 42 Vimpat R 42 PARI eFlow 42 tubulin inhibitor 42 Kinoid 42 Zybrestat 42 sodium glucose cotransporter 42 AT# [002] 42 MNTX 42 pradefovir 42 agomelatine 42 Peginterferon 42 ALVESCO R 42 blinded randomized placebo controlled 42 fenofibric acid 42 Ramelteon 42 Drug Candidate 42 RP# [002] 42 investigational humanized monoclonal antibody 42 MAGE A3 ASCI 42 NovaDel 42 Buprenorphine Naloxone 42 Lung Rx 42 Zenvia TM 42 receptor agonists 42 AFFiRiS 42 Ropinirole 42 dimebon 42 rt PA 42 difluprednate 42 Taxotere ® 42 NOXXON 42 metaglidasen 42 ThGRF 42 methionine aminopeptidase 42 NUVIGIL 42 Amrubicin 42 Zoraxel TM 42 Avanafil 42 laquinimod 42 long acting bronchodilator 42 selective agonist 42 beta2 agonist 41 PEGylated interferon 41 aflibercept 41 avanafil 41 QLT# 41 Qutenza TM 41 ZYBRESTAT 41 Betaferon R 41 Droxidopa 41 Phase III placebo controlled 41 axitinib 41 PSN# [002] 41 Viibryd 41 HGS ETR1 41 CIMZIA TM certolizumab pegol 41 weekly subcutaneous injections 41 CDP# 41 Mirapexin R 41 μg dose 41 Initiates Clinical 41 Cytochrome P# 41 ONTARGET R 41 stated Michelle Berrey 41 REMUNE R 41 ACOMPLIA R 41 Nanobody ® 41 lumiliximab 41 Darunavir 41 diabetic neuropathic pain 41 PPAR gamma agonist 41 coadministration 41 preclinical studies 41 TH# [003] 41 XmAb# 41 epothilones 41 Busulfex 41 Nexavar sorafenib 41 VaD 41 Cimzia ® 41 Zolpimist 41 P2Y 41 tocilizumab 41 Phase IIIb 41 AVONEX ® 41 Balaglitazone 41 duloxetine 41 iniparib 41 BIIB# 41 AZILECT ® 41 VESIcare 41 cetrorelix 41 CERVARIX 41 TELINTRA 41 SCH # 41 selective A2A adenosine receptor 41 TQT study 41 O PPDS 41 mg dose 41 denileukin diftitox 41 sapacitabine 41 YONDELIS R 41 fipamezole 41 SYN# 41 acute exacerbations 41 Pegasys plus Copegus 41 INTEGRILIN 41 Perforomist ™ Inhalation Solution 41 RoACTEMRA 41 GRASPA ® 41 mu opioid receptor antagonist 41 receptor antagonists 41 Allovectin 7 R 41 PDE inhibitor 41 KN# [001] 41 Trobalt 41 XYZAL R 41 BEMA TM Fentanyl 41 tarenflurbil 41 Eszopiclone 41 acute ischemic stroke 41 Removab 41 DUROS 41 Loxapine 41 DOV Pharmaceutical 41 Initiated Phase 41 lixivaptan 41 PXD# 41 Bioral 41 AVN# [001] 41 preclinical efficacy 41 RPL# 41 ORENCIA ® 41 Ophthotech 41 ChronVac C ® 41 PNP inhibitor 41 FOLFIRINOX 41 tolerability 41 COMT inhibitors 41 excessive sleepiness 41 highly selective endothelin 41 IMC A# 41 nitric oxide donating prostaglandin 41 Debiopharm SA 41 refractory gout 41 Perindopril 41 MGd 41 LCP AtorFen 41 Lofexidine 41 aripiprazole Abilify 41 multicenter Phase II 41 frovatriptan 41 CAELYX 41 Fovea Pharmaceuticals 41 investigational compound 41 Bayer Onyx 41 Oglemilast 41 PD2i Analyzer 41 BCR ABL inhibitor 41 initiate Phase 1b 41 naproxen esomeprazole magnesium 41 risperidone Risperdal 41 Elagolix 41 nilotinib Tasigna 41 Keppra XR 41 ONCONASE 41 Prodarsan R 41 Kevetrin 41 antiplatelet agent 41 Degarelix 41 elvucitabine 41 Cardioxyl Pharmaceuticals 41 INCB# [002] 41 Addex Pharmaceuticals 41 NicVAX 41 MIV 41 ularitide 41 Phase III confirmatory 41 Lixivaptan 41 mGlu2 3 41 subcutaneous dose 41 XTLbio 41 SU# [003] 41 Multimeric 41 mRNA antagonists 41 MB# MB# 41 Quinamed 41 palonosetron 41 carbidopa levodopa 41 STEDESA 41 guanfacine extended release 41 investigational oral 41 RGB # 41 PF # [002] 41 Major Depressive Disorder MDD 41 bosutinib 41 drug GLPG# 41 loxapine 41 naproxcinod 41 darunavir ritonavir 41 muscarinic 41 pomalidomide 41 Unit Dose Budesonide 41 aplindore 41 Vimpat ® 41 Velcade bortezomib 41 pegylated 41 NLX P# 41 CDK inhibitor 41 circadian cytokine modulator 41 davalintide 41 seliciclib CYC# 41 Zoloft sertraline 41 targeted radiotherapeutic 41 CORT # 41 DYNEPO 41 belinostat 41 DB# [003] 41 Bevasiranib 41 Azilect ® 41 Pennsaid R 41 BioMarck 41 enoximone 41 induced macular edema 41 ANYARA 41 bortezomib Velcade R 41 Zomig 41 GABAA receptor complex 41 PRTX 41 PHARMACEUTICALS INC. 41 PA# [002] 41 oral FTY# 41 initiate Phase IIa 41 Lenalidomide 41 HYCAMTIN 41 Gemin X 41 enoximone capsules 41 oral cladribine 41 Romidepsin 41 CK # 41 TNF alpha inhibitor 41 Telmisartan 41 pregabalin 41 REG1 41 Nasulin 41 Onconova 41 epothilone 41 BENICAR 41 forodesine 41 Zebinix R 41 5 HT2A receptor 41 serotonin neurotransmission 41 Epothilone D 41 AVR# [001] 41 OncoGel 41 LEVADEX TM 41 NXN 41 Apixaban 41 SCIg 41 AAG geldanamycin analog 41 Universal Flu Vaccine 41 vernakalant 41 LAS# [002] 41 Nasulin ™ 41 JAK3 inhibitor 41 ILUVIEN ® 41 Antagonist 41 dasatinib Sprycel ® 41 Revotar 41 Luteinizing Hormone Releasing Hormone 41 pharmacodynamic 41 Requip XL 41 Stedivaze 41 ascending doses 41 ENVISION 41 TRBN 41 iobenguane 41 manufactures RISPERDAL ® CONSTA 41 MicroDose 41 highly selective adenosine 41 MAO B 41 bronchodilation 41 Dalbavancin 41 zileuton 41 biologic therapy 41 ISEL 41 Nasulin TM 41 NN# [001] 41 Posiphen 41 Trimesta 41 galiximab 41 Thorough QT 41 ocular formulation 41 Xeloda ® 41 Spiegelmer ® 41 Zalbin 41 RAPTIVA 41 Aurora kinase 41 alpha 2A 41 Novartis NVS Snapshot Report 41 refractory AML 41 Lurasidone 41 selective androgen receptor modulators 41 Trandolapril 41 Phase IIb trials 41 Inflazyme 41 RhuDex TM 41 confirmatory Phase III 41 EnVivo 41 SUTENT ® 41 Vidofludimus 41 NMDA receptor antagonist 41 NuroPro PD 41 dutogliptin 41 Leflunomide 41 methylnaltrexone 41 triphendiol 41 Abbott HUMIRA 41 interferon gamma 1b 41 INNO 41 Brinavess 41 atrasentan 41 Specifid 41 erlotinib Tarceva ® 41 Rivaroxaban 41 5 HT1A 41 DP b# 41 Jevtana 41 Ovonic TM 41 acting inhaled anticholinergic 41 oral Xeloda